ArticleCyborg and bionic systems (Washington, D.C.)2026
NIR-Propelled Biomimetic Nanomotors for Photothermal/Chemodynamic/NO Synergistic Tumor Therapy.
Article in Cyborg and bionic systems (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unveiling Photo-Thermal-Electrical Performance in Robust, Self-Healing, and Anti-Freezing Cellulose-MXene Eutectogels for Advanced Hemostasis.Nano-micro letters · 2026Article
- Magnetic/photothermal dual-driven micro/nanorobots for synergistic NO-mediated photothermal thrombolysis.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multimodal nanotherapeutic systems capable of integrating photothermal, catalytic, and gas-mediated strategies offer powerful opportunities to overcome the limitations of single-mode cancer therapies. Here, we develop a near-infrared (NIR) light-activated biomimetic nanomotor for targeted nitric oxide (NO) delivery and synergistic cancer therapy. The nanomotor is constructed from bowl-shaped mesoporous polydopamine nanoparticles loaded with Fe(II) as a Fenton catalyst and BNN6 as a thermally responsive NO donor (denoted as PFB). To endow tumor specificity, the nanomotor is further camouflaged with MCF-7 cancer cell membrane (PFB@CM), enabling homologous recognition and enhanced intratumoral accumulation. Upon NIR irradiation, PFB@CM exhibits strong photothermal conversion efficiency that initiates 3 synergistic processes: (a) self-thermophoretic propulsion that promotes cellular internalization; (b) heat-triggered decomposition of BNN6 for precise NO release; and (c) heat-accelerated Fe(II) release from the polydopamine matrix. The liberated Fe(II) catalyzes endogenous H
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.